Details of the Drug

General Information of Drug (ID: DM1NTVQ)

Drug Name
Tadekinig alfa
Indication
Disease Entry ICD 11 Status REF
XIAP deficiency 4A01.22 Phase 3 [1]
Drug Type
Recombinant protein
Cross-matching ID
DrugBank ID
DB14858
TTD ID
DF6UP7

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-18 (IL18) TTRICUF IL18_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease XIAP deficiency
ICD Disease Classification 4A01.22
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-18 (IL18) DTT IL18 1.46E-01 0.12 1.81
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03512314) Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of AB2 Bio.